• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

澳大利亚人群中的异喹胍氧化作用。

Debrisoquine oxidation in an Australian population.

作者信息

Peart G F, Boutagy J, Shenfield G M

出版信息

Br J Clin Pharmacol. 1986 May;21(5):465-71. doi: 10.1111/j.1365-2125.1986.tb02827.x.

DOI:10.1111/j.1365-2125.1986.tb02827.x
PMID:3718805
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1401023/
Abstract

The standard laboratory method for determination of debrisoquine phenotype has been modified and shortened with no loss of sensitivity. Debrisoquine metabolic ratios (MR) at 4 and 8 h showed excellent correlation indicating that collection time can also be shortened. Same day phenotyping is therefore possible. One hundred normal, Caucasian Australian subjects were phenotyped (46 males, 54 females) and 6% were poor metabolisers (PM) of debrisoquine. Fifty of the original subjects were also acetylation phenotyped and 34% were fast and 66% slow acetylators. One PM of debrisoquine was a fast acetylator of sulphadimidine and four PM were slow acetylators. This was a non-significant association.

摘要

用于确定异喹胍代谢表型的标准实验室方法已得到改进和简化,且灵敏度未受损失。4小时和8小时时的异喹胍代谢率(MR)显示出极佳的相关性,这表明采集时间也可以缩短。因此,同一天进行表型分析是可行的。对100名澳大利亚白种人正常受试者进行了表型分析(46名男性,54名女性),其中6%为异喹胍慢代谢者(PM)。对最初的50名受试者也进行了乙酰化表型分析,其中34%为快乙酰化者,66%为慢乙酰化者。一名异喹胍PM是磺胺二甲嘧啶的快乙酰化者,四名PM是慢乙酰化者。这是一种无显著意义的关联。

相似文献

1
Debrisoquine oxidation in an Australian population.澳大利亚人群中的异喹胍氧化作用。
Br J Clin Pharmacol. 1986 May;21(5):465-71. doi: 10.1111/j.1365-2125.1986.tb02827.x.
2
Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population.
Zhongguo Yao Li Xue Bao. 1990 Sep;11(5):385-8.
3
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.泰国人群中异喹胍多态性氧化的证据。
Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x.
4
N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex.
Int J Clin Pharmacol Ther Toxicol. 1990 Dec;28(12):504-9.
5
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
6
Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.芬兰人群中的异喹胍氧化:口服避孕药对代谢率的影响。
Br J Clin Pharmacol. 1988 Dec;26(6):791-5. doi: 10.1111/j.1365-2125.1988.tb05321.x.
7
Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.甲苯磺丁脲代谢与异喹胍氧化表型之间缺乏相关性。
Eur J Clin Pharmacol. 1987;33(4):397-402. doi: 10.1007/BF00637637.
8
Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.安非他明在异喹胍代谢快和代谢慢的人群中的代谢氧化作用。
Eur J Clin Pharmacol. 1982;23(2):147-50. doi: 10.1007/BF00545969.
9
Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.美托洛尔在白种人和尼日利亚人中的立体选择性代谢——与异喹胍氧化表型的关系。
Br J Clin Pharmacol. 1989 May;27(5):613-6. doi: 10.1111/j.1365-2125.1989.tb03424.x.
10
Genetically determined oxidation capacity and the disposition of debrisoquine.遗传决定的氧化能力与异喹胍的代谢
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.

引用本文的文献

1
An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.对 5408 名澳大利亚患者 CYP2D6、CYP2C19、CYP2C9 和 VKORC1 基因进行基因分型后的等位基因、基因型和表型频率、可操作的药物基因组学 (PGx) 变异体和表型转化分析。
J Neural Transm (Vienna). 2019 Jan;126(1):5-18. doi: 10.1007/s00702-018-1922-0. Epub 2018 Sep 6.
2
Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.去甲丙咪嗪,CYP2D6 活性的底物:群体药代动力学模型和药物相互作用试验的设计要素。
Br J Clin Pharmacol. 2010 Oct;70(4):523-36. doi: 10.1111/j.1365-2125.2010.03731.x.
3
Genetically determined sparteine oxidation polymorphism in a Polish population.
Eur J Clin Pharmacol. 1994;46(5):481-3. doi: 10.1007/BF00191917.
4
Propafenone in the treatment of cardiac arrhythmias. A risk-benefit appraisal.普罗帕酮治疗心律失常。风险效益评估。
Drug Saf. 1995 Jan;12(1):55-72. doi: 10.2165/00002018-199512010-00005.
5
Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.甲苯磺丁脲代谢与异喹胍氧化表型之间缺乏相关性。
Eur J Clin Pharmacol. 1987;33(4):397-402. doi: 10.1007/BF00637637.
6
Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.通过收集健康志愿者每小时的尿液来测定异喹胍代谢率。
Br J Clin Pharmacol. 1987 Dec;24(6):827-9. doi: 10.1111/j.1365-2125.1987.tb03254.x.
7
Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.芬兰人群中的异喹胍氧化:口服避孕药对代谢率的影响。
Br J Clin Pharmacol. 1988 Dec;26(6):791-5. doi: 10.1111/j.1365-2125.1988.tb05321.x.
8
Clinical pharmacokinetics of imipramine and desipramine.丙咪嗪和地昔帕明的临床药代动力学
Clin Pharmacokinet. 1990 May;18(5):346-64. doi: 10.2165/00003088-199018050-00002.
9
Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.对乙酰氨基酚和非那西丁的代谢与异喹胍氧化表型的关系。
Eur J Clin Pharmacol. 1991;40(6):547-52. doi: 10.1007/BF00279967.
10
Debrisoquine oxidation polymorphism in a Tasmanian population.塔斯马尼亚人群中的异喹胍氧化多态性。
Eur J Clin Pharmacol. 1991;40(5):529-32. doi: 10.1007/BF00315235.

本文引用的文献

1
Debrisoquine hydroxylation capacity: problems of assessment in two populations.异喹胍羟基化能力:两个群体中的评估问题。
Clin Pharmacol Ther. 1981 Feb;29(2):218-23. doi: 10.1038/clpt.1981.35.
2
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
3
A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report.一种区分三种乙酰化表型的简单药代动力学方法:初步报告。
Br J Clin Pharmacol. 1982 Mar;13(3):375-8. doi: 10.1111/j.1365-2125.1982.tb01388.x.
4
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.药物氧化缺陷:药代动力学及治疗学意义
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
5
The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.去甲丙咪嗪羟基化试验可预测地昔帕明的稳态血药浓度。
Br J Clin Pharmacol. 1983 Mar;15(3):388-90. doi: 10.1111/j.1365-2125.1983.tb01518.x.
6
Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.美芬妥英的药物遗传学:人类一种新的药物羟基化多态性
Eur J Clin Pharmacol. 1984;26(6):753-9. doi: 10.1007/BF00541938.
7
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.患有哌克昔林神经病变患者的异喹胍氧化受损。
Br Med J (Clin Res Ed). 1982 Jan 30;284(6312):295-9. doi: 10.1136/bmj.284.6312.295.
8
Assessment of the drug metabolism capacity of the liver.肝脏药物代谢能力的评估。
Br J Clin Pharmacol. 1982 Nov;14(5):631-51. doi: 10.1111/j.1365-2125.1982.tb04950.x.
9
An improved and simplified method of detecting the acetylator phenotype.一种检测乙酰化酶表型的改良简化方法。
J Med Genet. 1969 Dec;6(4):405-7. doi: 10.1136/jmg.6.4.405.
10
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.采用气相色谱-火焰离子化和氮选择性检测法测定生物流体中的异喹胍及其4-羟基代谢物。
J Chromatogr. 1977 Mar 11;133(1):161-6. doi: 10.1016/s0021-9673(00)89216-x.